Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Collaborative Program to Develop Treatment Options for Systemic Lupus Erythematosus

By BiotechDaily International staff writers
Posted on 11 Feb 2013
A collaborative agreement between an American biomedical research institute and a European pharmaceutical manufacturer will promote the development of antibodies for treatment of systemic lupus erythematosus (SLE).

SLE is a potentially fatal inflammatory, multisystemic, autoimmune disease of the connective tissue, characterized by fever, skin lesions, joint pain or arthritis, and anemia. The disease often affects the kidneys, spleen, heart, and various other organs. SLE occurs nine times more often in women than in men, especially in women in the childbearing years ages 15 to 35, and is more common in those of non-European descent. There is no cure for SLE, and the goal of treatment has been to control symptoms.

To promote development of treatments for SLE the pharmaceutical company Merck Serono (Darmstadt, Germany) will collaborate with the Feinstein Institute for Medical Research (Manhasset, NY, USA). Merck Serono, which is the biopharmaceutical division of Merck KGaA, discovers, develops, manufactures, and markets prescription medicines of both chemical and biological origin. The Feinstein Institute for Medical Research is the research branch of the North Shore-Long Island Jewish Health System. It maintains more than 800 scientists and investigators who are conducting research in oncology, immunology and inflammation, genetics, psychiatry, neurology, pediatrics, surgery, urology, obstetrics/gynecology, and many other specialties.

Under terms of the collaborative agreement, Merck Serono will fund a research program at the Feinstein Institute and be responsible for the development and commercialization of the antibodies resulting from the collaboration. The program will focus on the use of antibodies to inhibit the action of certain proteins responsible for inflammation in the pathogenesis of SLE.

“There is a very high unmet medical need for novel therapies to treat systemic lupus erythematosus. Over the last fifty years, only one new treatment option has been approved to treat the disease,” said Dr. Bernhard Kirschbaum, executive vice-president, head of global research and early development at Merck Serono. “The Feinstein Institute is at the forefront of translational research in inflammatory and autoimmune diseases and this is a rare opportunity for our researchers to collaborate with key experts in the field of systemic lupus erythematosus to develop alternative therapeutic approaches, and further strengthen our research capabilities in the field of immunology.”

“We are delighted to collaborate with Merck Serono to develop therapeutics for lupus with the potential to treat the underlying causes of the disease,” said Dr. Betty Diamond, head of the center for autoimmune and musculoskeletal diseases at the Feinstein Institute. “The resources of Merck Serono will be an important addition to our efforts to provide new antibody therapeutics targeted at inflammatory processes. These mechanisms are critical to solving the problem of lupus and many other autoimmune diseases.”

Related Links:
Merck Serono
Feinstein Institute for Medical Research




comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.